Q-omics provides the consensus-scored KLHDC3 profile across patient tissues and cancer cell-line models. KLHDC3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KLHDC3 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, KLHDC3 RNA expression shows 18,829 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KICH, and ACC as cancer lineages where KLHDC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHDC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHDC3 survival associations across molecular data types. KLHDC3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHDC3 RNA expression–survival associations across cancer types. High KLHDC3 expression shows unfavorable associations in LIHC, ACC and UCEC, but favorable associations in UVM, LGG and OV. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for KLHDC3 RNA expression.
This table summarizes KLHDC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KLHDC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHDC3 shows lower tumor expression in KICH and higher tumor expression in LIHC, BLCA, COAD, LUSC and HNSC. The KICH box plot shows higher KLHDC3 RNA expression in normal versus tumor tissue (log2 FC = −1.681, t-test p < 0.001).
This table shows molecular features associated with KLHDC3 in patient tissues and cancer cell lines. In patient samples, KLHDC3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHDC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
